Abstract

The Role of Targeted Therapy in Systemic Lupus Erythematosus: Current Advances and Future Perspectives

Author(s): David Brooks*

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multi-organ inflammation and immune system dysfunction. Despite significant advancements in the treatment of SLE, many patients still experience disease flares, irreversible organ damage, and poor long-term outcomes. The treatment of SLE has historically relied on nonspecific immunosuppressive agents, such as corticosteroids and antimalarials, which provide symptomatic relief but do not directly target the underlying immune dysregulation. Over the past decade, the advent of targeted therapies has transformed the management of SLE, offering more specific mechanisms of action and potentially fewer side effects. This article reviews the role of targeted therapies in the treatment of SLE, with a focus on biologic agents, Janus kinase (JAK) inhibitors, and other innovative treatments. We also explore the challenges and future directions of targeted therapy in SLE, including personalized medicine approaches and ongoing clinical trials.